Carcinoma en cuirasse.

Carcinoma en cuirasse. Proc (Bayl Univ Med Cent). 2019 Apr;32(2):263-265 Authors: Culver AL, Metter DM, Pippen JE Abstract Carcinoma en cuirasse (CeC) is an extremely rare form of cutaneous metastasis of breast cancer. Guidelines for diagnosis and treatment of CeC are limited due to the small number of reported cases. It can be difficult to distinguish CeC from benign etiologies on initial presentation, but CeC can be easily distinguished by histopathology. Treatment of CeC focuses on palliation with no consensus on therapy guidelines. Treatment modalities that have been explored include chemotherapy, radiotherapy (with or without local hyperthermia), and hormonal antagonists. Here we present a 62-year-old woman with recurrent triple-negative breast cancer manifesting as CeC to the chest wall. PMID: 31191149 [PubMed]
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Tags: Proc (Bayl Univ Med Cent) Source Type: research

Related Links:

Invasive triple ‐negative apocrine carcinoma (TNAC) of the breast is a rare type of triple‐negative breast cancer. Furthermore, the clinicopathological features, prognosis of TNAC, and the potential effect of systemic treatments on TNAC remain unclear. The purpose of the present study was to gain better knowled ge of clinicopathological features and survival differences in patients with TNAC and TNBC (non‐apocrine breast cancer), by utilizing a population wide database to enroll a large population of breast cancer. AbstractBackgroundTriple ‐negative apocrine carcinoma (TNAC) of the breast is a very rare type of bre...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionIt is important to maintain a suspicion for GI tract metastasis in breast cancer patients who present with abdominal mass or GI symptoms, as this aids in prompt institution of accurate and appropriate management.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
CONCLUSION: The pre-treatment tumor SUVmax could be utilized as an independent imaging biomarker of the tumor aggressiveness and poor prognosis. Risk stratification based on this index could play a pivotal role in alteration of treatment planning, such as neoadjuvant chemotherapy (precision oncology). PMID: 31587025 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
ConclusionsMRI demonstrated good accuracy in predicting pCR after NAC among the breast cancer patients examined. However, non-mass enhancement at pre-treatment MRI negatively affected the diagnostic performance of MRI in assessing treatment response after NAC.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Conclusions: SCC of the breast is a very aggressive tumor, and adjuvant chemotherapy should be strongly considered.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsAn exercise program appears to be beneficial for QoL, particularly in the physical functioning of breast cancer survivors. Moreover, it seems to have an important role on strength levels.Legal entity responsible for the studyAssocia ção de Investigação e Cuidados de Suporte em Oncologia.FundingLiga Portuguesa Contra o Cancro.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe outcome of selected apocrine triple negative breast cancer patients is excellent and possibly deserves a treatment de-escalation. Multicenter projects focusing on the possibility to avoid adjuvant chemotherapy in selected subtypes of triple negative breast cancers with favorable outcome are warranted.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureG. Cancello: Honoraria (self): Pierre Fabre. E. Montagna: Honoraria (self): Pierre fabre; Honoraria (self): gentili. E. Munzone: Honoraria (institution), Advisory / Consultancy: Pierre Fabre; Honoraria (institution), ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.MethodsWe reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.ResultsIn total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n  = 27,385...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe density of tumor-infiltrating lymphocytes (TIL) is a predictive factor for response to neoadjuvant systemic therapy (NAST) in breast cancer. High TIL density correlates with higher complete pathologic remission (pCR) in triple negative and HER2 positive breast cancer. Additionally, not only TIL density but also subsets of immune cells in tumor stroma seem to play an important role in cancer and immune cell interaction and response to chemotherapy. Our aim is to determine TIL density and expression of CD 20, CD3, CD8, PD-L1, FOXP3 and PGM1 on core biopsy specimen and find a correlation with pCR.Trial d...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe results of our study could be useful for enhance the role of MTD and identify unmet needs in decision making process in EBC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Hormones | Universities & Medical Training